Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566265 · ClinicalTrials.gov registry record · Phase 2
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT02566265: Completed Phase 2 study, sponsored by Yale University.
NCT02566265 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 122 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02566265, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The investigators' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly, will reduce influenza-related morbidity, reduce interruptions in cancer therapy and may reduce disease progression at the end of the flu season
Primary Outcome
Any documented flu infection during the 2015-2016 flu season or evidence of disease progression.
Interventions
- BIOLOGICAL Fluzone High Dose Vaccine
- BIOLOGICAL Standard of care/Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
What the finished NCT02566265 record still lists
NCT02566265 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Fluzone High Dose Vaccine is the first listed.
NCT02566265 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02566265 about?
NCT02566265 is a clinical study titled "Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients". The investigators' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly, will reduce influenza-related morbidity, reduce interruptions in cancer...
What is the current status of trial NCT02566265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2015-09. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02566265?
The interventions under investigation include: Fluzone High Dose Vaccine (BIOLOGICAL), Standard of care/Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02566265?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02566265's enrollment target sits among peer trials
122 565th of 2000 higher than 1,434 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia